Product image of Lacosamid Vivanta (Lacosamide) supplied by GNH India

Lacosamid Vivanta

Active Ingredient:
Lacosamide
Origin:
EU

Lacosamid Vivanta (Lacosamide)

Lacosamide, the active ingredient in Lacosamid Vivanta, is an anti‑epileptic presented as an intravenous solution for intravenous use. It is employed in the management of partial‑onset seizures and broader epilepsy syndromes, particularly when rapid plasma concentrations are required or oral administration is not feasible. The drug works by modulating neuronal excitability through sodium channel inactivation, helping to reduce seizure frequency in affected patients and improving overall neurological stability.

GNH India supplies Lacosamid Vivanta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Vivanta Generics S.R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lacosamide is an anti‑epileptic medication used to control seizure activity in the central nervous system.

  • Partial‑onset seizures: Reduces seizure frequency when used as adjunctive therapy.
  • Epilepsy (generalized): Provides seizure control as part of comprehensive management.
  • Status epilepticus (intravenous): Offers rapid seizure control in acute settings.

How It Works

  • Lacosamide enhances the slow inactivation phase of voltage‑gated sodium channels in neuronal membranes. By stabilizing the inactive state of these channels, it diminishes repetitive neuronal firing and reduces hyper‑excitability that underlies seizure generation. The drug does not significantly affect fast inactivation, allowing normal neuronal conduction while selectively targeting pathological activity. Additionally, lacosamide may modulate calcium channel activity, contributing to its anticonvulsant profile.

Side Effects

Lacosamide may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Dizziness: Sensation of light‑headedness or unsteady balance.
  • Nausea: Feeling of stomach upset or urge to vomit.
  • Headache: Mild to moderate cranial pain.
  • Fatigue: Unusual tiredness or lack of energy.
  • Visual disturbances: Blurred vision or double vision.

Serious or Rare Side Effects

  • Cardiac conduction abnormalities: Prolongation of PR interval or atrioventricular block.
  • Severe dermatologic reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Suicidal thoughts or behavior: Emergence of new or worsening psychiatric symptoms.

Precautions & Warnings

When prescribing Lacosamid Vivanta, clinicians should consider several safety measures.

  • Renal impairment: Adjust dosing or monitor plasma levels.
  • Hepatic impairment: Use with caution and monitor liver function.
  • Concomitant cardiac drugs: Monitor ECG for potential conduction changes.
  • Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus.
  • Driving or operating machinery: Caution due to possible dizziness or visual effects.
  • Store at ambient temperature: Keep in the original container, protect from moisture and light.

Avoid Interactions

Lacosamide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Carbamazepine: Decreases lacosamide plasma concentrations, reducing efficacy.
  • Other sodium channel blockers (e.g., phenytoin, lamotrigine): May increase risk of central nervous system depression.
  • Strong CYP3A4 inducers (e.g., rifampin): May lower lacosamide levels.

Moderate Interactions (Monitor Closely)

  • Oral contraceptives: May have reduced effectiveness.
  • Antihypertensive agents: Potential additive hypotensive effect.
  • Alcohol: May enhance dizziness and CNS depression.

Frequently Asked Questions

Lacosamid Vivanta is an intravenous formulation of lacosamide, an anti‑epileptic drug indicated for the treatment of partial‑onset seizures and for broader epilepsy management, including acute control of status epilepticus when rapid drug delivery is required.

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilizes the inactive state of the channels, reducing repetitive neuronal firing and lowering the hyper‑excitability that leads to seizure activity.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s clinical condition, weight, renal and hepatic function, and response to therapy. No standardized dosing regimen is provided here.

Safety data for lacosamide in pregnancy and lactation are limited. Use is generally reserved for situations where the potential therapeutic benefit outweighs any possible risk to the fetus or infant, and decisions should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with older sodium‑channel blockers such as carbamazepine, lacosamide offers a distinct mechanism by targeting slow inactivation, which may result in fewer drug‑interaction issues. It is also available as an IV formulation, providing rapid plasma levels that oral agents like levetiracetam cannot achieve in emergency settings.

Lacosamid Vivanta should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from moisture and direct light. Do not freeze. Inspect the container for any particulate matter before use.

The product is given by intravenous infusion. The rate and duration of infusion are set by the healthcare professional, typically over a period of 15‑30 minutes, depending on the clinical scenario and patient tolerance.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation or atrioventricular block, severe skin reactions like Stevens‑Johnson syndrome, and emergence of suicidal thoughts or behavior. Prompt monitoring and immediate medical attention are required if these occur.

Patients with known hypersensitivity to lacosamide or any component of the formulation should avoid use. Those with pre‑existing severe cardiac conduction disorders, such as second‑ or third‑degree AV block, should not receive the drug without careful cardiac monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.